VivoSeq
Other

B-ALL

3

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

B-ALL is an early-stage landscape with 3 programs across 1 company. The most active players are Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Tslpr-Cart

National Cancer Institute (NCI)

Cyclophosphamide

Baxter Healthcare Corporation

Fludarabine

Sanofi

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

11

clinical trials

Recruiting4 · 36%
Active, not recruiting2 · 18%
Not yet recruiting2 · 18%
Unknown status2 · 18%
Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

CAV Regimen for R/R Ph- B-ALL
Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05657652·36 enrolled
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Recruiting·PPeking University People's Hospital·Phase 1/2·NCT06880913·30 enrolled
Co-administration of CART22-65s and huCART19 for B-ALL
Recruiting·SStephan Grupp MD PhD·Phase 1/2·NCT05674175·93 enrolled
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05621291·60 enrolled
A Multi-center Retrospective Study of INO Treating B-ALL
Active, not recruiting·RRuijin Hospital·N/A·NCT07238907·102 enrolled
Venetoclax Plus Inotuzumab for B-ALL
Active, not recruiting·—·Phase 1·NCT05016947·23 enrolled
Allogeneic UCB-derived CAR-T for B-ALL
Not yet recruiting·TThe General Hospital of Western Theater Command·Phase 1·NCT07256353·50 enrolled
Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)
Not yet recruiting·National Cancer Institute (NCI)·Phase 1·NCT07572136·57 enrolled
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Withdrawn·—·Phase 1·NCT03768310
CART-19 Cells For R/R B-ALL
Unknown status·FFujian Medical University·Phase 2/3·NCT03391739·20 enrolled
ThisCART19A Bridging to alloHSCT for R/R B-ALL
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT05679687·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)